Clinical Trials
Retatrutide Phase 3 Results: The Complete TRIUMPH Program Guide 2026
Eli Lilly's retatrutide (LY3437943) delivered 28.7% weight loss in its first Phase 3 readout. This 2026 guide breaks down every TRIUMPH trial, what the data means, and when FDA approval could land.